OncoMatch/Clinical Trials/NCT07002034
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Is NCT07002034 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies RE104 for for adjustment disorder.
Treatment: RE104 for — The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other illnesses such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease (PD) or Idiopathic Pulmonary Fibrosis (IPF) as compared to active-placebo.
Check if I qualifyEligibility summary
For patients with Adjustment Disorder.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- UAB, Psychiatry and Behavioral Neurology · Birmingham, Alabama
- University of Arizona · Tucson, Arizona
- Kadima Neuropsychiatry Institute · San Diego, California
- Providence Medical Foundation · Santa Rosa, California
- University of Colorado · Aurora, Colorado
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify